Scenic Biotech BV announces $31m financing
Scenic Biotech BV will use an incoming $31m (28) Series A financing to advance its pipeline of genetic modifiers, a new molecular entity in cancer and rare disease.
·
Scenic Biotech BV will use an incoming $31m (28) Series A financing to advance its pipeline of genetic modifiers, a new molecular entity in cancer and rare disease.
·
French venture capital expert Kurma Partners has closed its Growth Opportunities Fund at 160m and targets a final closing at 250m.
Moderna will build its first mRNA production facility in Kenya, investing up to US$500m.
IgE cancer antibody specialist Epsilogen Ltd has closed a £30.75m round led by Novartis Venture Fund to advance Phase Ib studies with MOv18 IgE in platinum-resistant ovarian cancer.
AbbVie has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie’s neuroscience portfolio.
Paris-based Meletios Therapeutics SA has licenced know-how from the Institut Pasteur for the development of a new class of antivirals-
TargED Biopharmaceuticals will use 39m from a Series A financing to bring its thrombolytic treatment to patients.
The cellular agriculture spin-off Onego Bio Ltd has been seeded with 10m to use its Trichoderma platform to establish an animal-free egg protein production.
The former mRNA start-up Moderna Inc is set to expand its commercial network in six European nations to become a gobally active vaccine company.
Antimicrobial resistance specialist Centauri Therapeutics Ltd has closed a £24m Series A round to identify novel therapeutic candidates using the Alphamer technology.